P. Merkel

P. Merkel, L. Moreland, L. Zgaga, 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.

P. Merkel, J. Stone, John C. Davis, 2006, Arthritis and rheumatism.

A novel approach to conducting clinical trials in the community setting: utilizing patient-driven platforms and social media to drive web-based patient recruitment

Artemio Ramirez, J. Krischer, P. Merkel, 2019, BMC Medical Research Methodology.

Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review.

P. Merkel, P. Monach, Lindsay M. Arnold, 2010, Arthritis and rheumatism.

Pulmonary Eosinophilic Granulomatosis with Polyangiitis has IgG4 Plasma Cells and Immunoregulatory Features.

M. Yandell, P. Merkel, F. Clayton, 2020, The American journal of pathology.

Serum Biomarkers in Patients with Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)

P. Merkel, J. Zwerina, P. Monach, 2015, PloS one.

Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis.

P. Merkel, C. Kallenberg, E. Matteson, 2011, Journal of the American Society of Nephrology : JASN.

IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis

P. Merkel, J. Stone, John C. Davis, 2011, Proceedings of the National Academy of Sciences.

Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.

A. Levin, P. Merkel, V. Tesar, 2020, The New England journal of medicine.

Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis

P. Merkel, J. Dawson, J. Shea, 2017, Rheumatology International.

Patient Perceptions and Preferences Regarding Telemedicine for Autoimmune Rheumatic Diseases Care During the COVID‐19 Pandemic

P. Merkel, M. Danila, J. Curtis, 2022, Arthritis care & research.

Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis

P. Merkel, L. Moreland, P. Monach, 2022, Interactive journal of medical research.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

Clinical Manifestations and Long‐Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America

P. Merkel, L. Moreland, S. Chung, 2021, ACR open rheumatology.

Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis.

P. Merkel, K. Maksimowicz-McKinnon, P. Monach, 2015, Rheumatology.

Thromboembolism—Another Threat to the Polymorbid Patient with Vasculitis?: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener’s Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 142: 620–626, 2005

P. Merkel, J. Stone, John C. Davis, 2005 .

Rituximab for the Treatment of Relapses in ANCA-associated Vasculitis

P. Merkel, J. Stone, L. Viviano, 2014 .

Rituximab for the Treatment of Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

P. Merkel, J. Stone, L. Viviano, 2014, Arthritis & rheumatology.

An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis.

P. Merkel, B. Shea, G. Tómasson, 2022, Seminars in arthritis and rheumatism.

Venous thromboembolism in ANCA-associated vasculitis. A population-based cohort study.

P. Merkel, D. Jayne, M. Segelmark, 2021, Rheumatology.

Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial

P. Merkel, P. Bekker, D. Jayne, 2020, JMIR Research Protocols.

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis

P. Merkel, M. Weisman, M. Nodale, 2020, Annals of the Rheumatic Diseases.

Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2019, Arthritis & rheumatology.

Outcomes of Nonsevere Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated With Glucocorticoids

P. Merkel, J. Stone, C. Kallenberg, 2015, Arthritis & rheumatology.

L50. The future of international clinical trials in vasculitis.

P. Merkel, P. Merkel, 2013, Presse medicale.

chapter 41 – Overview of Vasculitis

P. Merkel, P. Merkel, 2006 .

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

S. Yancey, P. Merkel, F. Moosig, 2017, The New England journal of medicine.

Eosinophils in Health and Disease: A State-of-the-Art Review.

P. Howarth, P. Merkel, A. Wardlaw, 2021, Mayo Clinic proceedings.

Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.

S. Yancey, P. Merkel, F. Moosig, 2019, The Journal of allergy and clinical immunology.

Cutaneous Manifestations of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

P. Merkel, Z. C. Chiesa Fuxench, R. Luqmani, 2020, Arthritis & rheumatology.

Peripheral neuropathy in antineutrophil cytoplasmic antibody-associated vasculitides

P. Merkel, R. Luqmani, A. Bischof, 2019, Neurology: Neuroimmunology & Neuroinflammation.

Genetic Variants in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Bayesian Approach and Systematic Review

K. Siminovitch, C. Amos, P. Merkel, 2019, Journal of clinical medicine.

Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2019, Arthritis & rheumatology.

Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

D. Schroeder, P. Merkel, J. Stone, 2018 .

Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

D. Schroeder, P. Merkel, J. Stone, 2018, Arthritis & rheumatology.

Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody–associated vasculitis

P. Merkel, R. Luqmani, R. Watts, 2017, Rheumatology.

Myeloperoxidase–Antineutrophil Cytoplasmic Antibody (ANCA)–Positive and ANCA‐Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets

P. Merkel, J. Stone, C. Kallenberg, 2016, Arthritis & rheumatology.

Allosteric modulation of proteinase 3 activity by anti-neutrophil cytoplasmic antibodies in granulomatosis with polyangiitis.

P. Merkel, J. Stone, John C. Davis, 2015, Journal of autoimmunity.

K. Siminovitch, L. Farrer, P. Merkel, 2014 .

Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.

P. Merkel, J. Stone, C. Kallenberg, 2013, Arthritis and rheumatism.

Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis.

P. Merkel, C. Kallenberg, E. Matteson, 2011, Arthritis and rheumatism.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

Long‐Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis

J. Block, P. Merkel, L. Moreland, 2020, Arthritis care & research.

Sequence‐Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in ADA2

P. Merkel, E. Remmers, D. Kastner, 2020, Arthritis & rheumatology.

Activation of a Latent Epitope Causing Differential Binding of Anti-Neutrophil Cytoplasmic Antibodies to Proteinase 3

P. Merkel, J. Stone, C. Kallenberg, 2019, bioRxiv.

Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis

D. Schroeder, P. Merkel, J. Stone, 2018, Rheumatology.

Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis

P. Merkel, J. Stone, E. S. St. Clair, 2017, Clinical and experimental immunology.

Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial

P. Merkel, K. Mynard, C. McAlear, 2017, Trials.

Are the 1990 American College of Rheumatology vasculitis classification criteria still valid?

P. Merkel, A. Judge, J. Robson, 2017, Rheumatology.

Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis

P. Merkel, C. Kallenberg, E. Matteson, 2011, Annals of the rheumatic diseases.

Clinical associations of renal involvement in ANCA-associated Vasculitis.

P. Merkel, G. Mayer, L. Quintana, 2020, Autoimmunity reviews.

Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index

P. Merkel, V. Tesar, A. Vaglio, 2010, Annals of the rheumatic diseases.

Consensus statement: Guide to bone health and disease in cystic fibrosis

P. Merkel, N. Watts, M. Holick, 2005 .

Consensus Conference Report: Guide to Bone Health and Disease in Cystic Fibrosis

P. Merkel, N. Watts, M. Holick, 2004 .

Relationship Between Markers of Platelet Activation and Inflammation with Disease Activity in Wegener’s Granulomatosis

P. Merkel, J. Stone, J. Freedman, 2011, The Journal of Rheumatology.

Comparison between the standard anticardiolipin antibody test and a new phospholipid test in patients with connective tissue diseases.

P. Merkel, Y. Chang, S. Pierangeli, 1999, The Journal of rheumatology.

Effects of the COVID‐19 Pandemic on Patients Living With Vasculitis

P. Merkel, M. Danila, J. Gordon, 2020, ACR open rheumatology.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody–associated Vasculitis

P. Tugwell, J. Farrar, P. Merkel, 2017, The Journal of Rheumatology.

The Journal of Rheumatology associated Vasculitis − Antineutrophil Cytoplasmic Antibody OMERACT Endorsement of Patient-reported Outcome Instruments in

P. Tugwell, J. Farrar, P. Merkel, 2017 .

A multicenter placebo-controlled study of methotrexate (MTX) in giant cell arteritis (GCA).

K. Kalunian, P. Merkel, J. Stone, 2000 .

Impact of vasculitis on employment and income.

P. Merkel, L. Barra, George C Casey, 2018, Clinical and experimental rheumatology.

Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort

P. Merkel, J. Robson, R. Luqmani, 2019, Arthritis & rheumatology.

Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.

P. Merkel, G. Hatemi, R. Stevens, 2015, The New England journal of medicine.

DRUG-INDUCED VASCULITES

P. Merkel, P. Merkel, 2001 .

Brief Communication: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study

P. Merkel, J. Stone, John C. Davis, 2005, Annals of Internal Medicine.

Drug-induced vasculitis.

P. Merkel, Peter A. Merkel, P. Merkel, 2001, Rheumatic diseases clinics of North America.

Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine.

P. Merkel, M. Slot, J. Niles, 2000, Arthritis and rheumatism.

ANCA-positive vasculitis associated with allopurinol therapy.

P. Merkel, Hyon K. Choi, J. Niles, 1998, Clinical and experimental rheumatology.

Alcohol-induced vasculitis: case report and commentary.

P. Merkel, K. Abuabara, W. James, 2014, Journal of the American Academy of Dermatology.

Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis

J. Krischer, P. Merkel, J. Stone, 2008, Annals of the rheumatic diseases.

Trends in bone mineral density in young adults with cystic fibrosis over a 15 year period.

P. Merkel, C. Gordon, J. Baker, 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Guide to bone health and disease in cystic fibrosis.

P. Merkel, N. Watts, M. Holick, 2005, The Journal of clinical endocrinology and metabolism.

Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis

E. Hoffman, Y. Hathout, H. Parikh, 2018, Steroids.

Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with ANCA‐Associated Vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2021, ACR open rheumatology.

Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis

P. Merkel, T. Mustelin, L. Moreland, 2022, Arthritis Research & Therapy.

Herpes zoster in immunocompromised patients: incidence, timing, and risk factors.

P. Merkel, J. Stone, John C. Davis, 2005, The American journal of medicine.

PP13. PHASE II STUDY OF THE SAFETY AND EFFICACY OF INFLIXIMAB IN GIANT CELL ARTERITIS (GCA): 22 WEEK INTERIM ANALYSIS

Mahboob Rahman, P. Merkel, J. Stone, 2005 .

Adverse Events in Connective Tissue Disease–Associated Pulmonary Arterial Hypertension

A. Praestgaard, P. Merkel, Nicole B Gabler, 2015, Arthritis & rheumatology.

Systemic Sclerosis Classification Criteria: Developing methods for multi-criteria decision analysis with 1000Minds

Mayes, P. Merkel, M. Baron, 2014 .

LB004A RANDOMIZED, CONTROLLED TRIAL OF RITUXIMAB VERSUS AZATHIOPRINE AFTER INDUCTION OF REMISSION WITH RITUXIMAB FOR PATIENTS WITH ANCA-ASSOCIATED VASCULITIS AND RELAPSING DISEASE

P. Merkel, D. Jayne, Rona M Smith, 2020 .

Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update

M. Dougados, M. D. de Wit, A. Iagnocco, 2022, Annals of the Rheumatic Diseases.

Measurement of functional status, self-assessment, and psychological well-being in scleroderma.

P. Merkel, Peter A. Merkel, 1998, Current opinion in rheumatology.

A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.

M. Mayes, P. Merkel, D. Furst, 2008, Arthritis and rheumatism.

Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.

A. Praestgaard, P. Merkel, Nicole B Gabler, 2015, American journal of respiratory and critical care medicine.

Comorbidities in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis versus the General Population

P. Merkel, M. Englund, G. Tómasson, 2016, The Journal of Rheumatology.

Alpha 1 -Antitrypsin Deficiency–Related Alleles Z and S and the Risk of Wegener’s Granulomatosis

P. Merkel, J. Stone, J. Edberg, 2011 .

Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT.

A. Levin, P. Merkel, L. Girard, 2022, Health technology assessment.

Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial

P. Merkel, W. Clark, N. Ives, 2013, Trials.

ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS)

P. Merkel, A. Judge, J. Robson, 2013, Clinical and Experimental Nephrology.

Measures of Response in Clinical Trials of Systemic Sclerosis: The Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS)

P. Tugwell, M. Mayes, P. Merkel, 2009, The Journal of Rheumatology.

Clinical trial design in scleroderma: where are we and where do we go next?

P. Merkel, D. Furst, C. Denton, 2012, Clinical and experimental rheumatology.

Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis.

P. Merkel, R. Lafyatis, E. Kissin, 2006, Arthritis and rheumatism.

Cocaine-associated cerebral vasculitis.

P. Merkel, W. Koroshetz, M. Cudkowicz, 1995, Seminars in arthritis and rheumatism.

Disease Activity, ANCA-Type, and Lipid Levels in ANCA-Associated Vasculitis.

P. Merkel, J. Stone, C. Kallenberg, 2019, Arthritis & rheumatology.

Updating OMERACT Core Set of Domains for ANCA-associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability, and Health

P. Tugwell, P. Merkel, A. Boonen, 2019, The Journal of Rheumatology.

Variation in the Treatment of Children Hospitalized With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in the US

P. Merkel, R. Xiao, P. Weiss, 2016, Arthritis care & research.

Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's)

S. Chow, P. Merkel, J. Stone, 2011, Arthritis care & research.

Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission

P. Merkel, J. Stone, E. S. St. Clair, 2022, Annals of the Rheumatic Diseases.

IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss).

P. Merkel, L. Moreland, P. Monach, 2017, Clinical and experimental rheumatology.

P. Merkel, P. Bekker, D. Jayne, 2019 .

Social Distancing, Health Care Disruptions, Telemedicine Use, and Treatment Interruption During the COVID‐19 Pandemic in Patients With or Without Autoimmune Rheumatic Disease

P. Merkel, M. Danila, J. Baker, 2021, ACR open rheumatology.

Clinical course and outcomes of childhood-onset granulomatosis with polyangiitis.

P. Merkel, R. Xiao, P. Weiss, 2016, Clinical and experimental rheumatology.

The future of damage assessment in vasculitis.

P. Merkel, J. Stone, C. Kallenberg, 2007, The Journal of rheumatology.

Hearing Loss in Wegener's Granulomatosis

P. Merkel, J. Spiegel, K. Grundfast, 2004, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise

P. Merkel, M. Baron, D. Furst, 2012, Arthritis care & research.

Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes

P. Merkel, D. Cella, C. Denton, 2020, Journal of scleroderma and related disorders.

Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7.

J. Krischer, D. Felson, P. Merkel, 2005, The Journal of rheumatology.

Diagnostic imaging in Takayasu arteritis

P. Merkel, E. Kissin, P. Merkel, 2004, Current opinion in rheumatology.

An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's)

J. Krischer, P. Merkel, P. Monach, 2013, Annals of the rheumatic diseases.

Rheumatic disease and cystic fibrosis.

P. Merkel, P. Merkel, Peter A. Merkel, 1999, Arthritis and rheumatism.

Developing a core set of outcome measure domains to study Raynaud's phenomenon and digital ulcers in systemic sclerosis: Report from OMERACT 2020.

P. Merkel, A. Herrick, Heiyoung Park, 2021, Seminars in arthritis and rheumatism.

Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.

R. Hays, M. Mayes, P. Merkel, 2005, The Journal of rheumatology.

Identification of Susceptibility Loci in IL6, RPS9/LILRB3, and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genome‐Wide Association Study

P. Merkel, J. Wren, T. Vyse, 2015, Arthritis & rheumatology.

Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations.

P. Merkel, J. Stone, John C. Davis, 2007, The Journal of rheumatology.

OP0238 Association between age at diagnosis and clinical presentation and outcomes of anca-associated vasculitis. analysis from the dcvas study

P. Merkel, R. Caporali, R. Watts, 2018, FRIDAY, 15 JUNE 2018.

B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis.

P. Merkel, R. Simms, M. Fritzler, 2009, Arthritis and rheumatism.

The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time.

P. Merkel, J. Stone, P. Bekker, 2022, Seminars in Arthritis & Rheumatism.

Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes.

D. T. Gray, Janet A. Blood, I. Bruce, 2020, Rheumatology.

New-onset hepatitis C virus-associated glomerulonephritis following sustained virologic response with direct-acting antiviral therapy .

P. Merkel, M. Palmer, D. Haddad, 2017, Clinical nephrology.

Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type

P. Merkel, J. Stone, Hyon K. Choi, 2015, Annals of the rheumatic diseases.

Psychometric properties of outcome measurement instruments for ANCA-associated vasculitis: a systematic literature review

P. Merkel, L. Carmona, S. Ramiro, 2022, Rheumatology.

Patient‐reported outcome assessment in vasculitis may provide important data and a unique perspective

P. Merkel, P. Seo, K. Herlyn, 2010, Arthritis care & research.

Early development of new cardiovascular risk factors in the systemic vasculitides.

P. Merkel, C. Klersy, C. Montecucco, 2019, Clinical and experimental rheumatology.

2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden

P. Merkel, C. Turesson, L. Jacobsson, 2014, Annals of the rheumatic diseases.

Plasma Exchange for ANCA-Associated Vasculitis: An International Survey of Patient Preferences

G. Guyatt, P. Merkel, D. Collister, 2022, Kidney medicine.

Thromboembolic disease in vasculitis

P. Merkel, P. Monach, G. Tómasson, 2009, Current opinion in rheumatology.

Thrombosis in Behçet ’ s disease

P. Merkel, P. Monach, G. Tómasson, 2008 .

Developing Methods to Link Patient Records across Data Sets that Preserve Patient Privacy

Judith Stephenson, Abiy Agiro, Xiaoxue Chen, 2020 .

Outcome measurements in scleroderma: results from a delphi exercise.

Richard W. Martin, M. Mayes, P. Merkel, 2007, The Journal of rheumatology.

Part 1: The need for novel treatment regimens for ANCA-associated vasculitis.

P. Merkel, P. Merkel, 2007, Clinical and experimental rheumatology.

Cardiac Involvement in Granulomatosis with Polyangiitis

P. Merkel, L. Moreland, P. Monach, 2015, The Journal of Rheumatology.

The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis

G. Guyatt, P. Merkel, D. Collister, 2022, BMJ.

Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6.

M. Suarez‐Almazor, P. Merkel, J. Reveille, 2003, The Journal of rheumatology.

Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

Richard W. Martin, M. Mayes, P. Merkel, 2002, Arthritis and rheumatism.

An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative

M. Mayes, P. Merkel, M. Baron, 2013 .

Dermatological Addendum to the 2012 International Chapel Hill Consensus Conference Nomenclature of Vasculitides

P. Merkel, J. Callen, S. Kawana, 2017 .

Prevalence of Antineutrophil Cytoplasmic Antibodies in a Large Inception Cohort of Patients with Connective Tissue Disease

P. Merkel, S. Skates, Yuchiao Chang, 1997, Annals of Internal Medicine.

Evaluation and treatment of vasculitis in the critically ill patient.

P. Merkel, Hyon K. Choi, J. Niles, 2002, Critical care clinics.

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management.

M. Humbert, P. Merkel, E. Bel, 2015, European journal of internal medicine.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

P. Merkel, J. Stone, C. Kallenberg, 2010, The New England journal of medicine.

Characterisation of the nasal microbiota in granulomatosis with polyangiitis

P. Merkel, K. Bittinger, R. Collman, 2018, Annals of the rheumatic diseases.

Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis.

J. Krischer, P. Merkel, J. Stone, 2011, Arthritis and rheumatism.

A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis

P. Merkel, J. Stone, John C. Davis, 2011, Arthritis care & research.

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis

H. Raspe, P. Merkel, D. Scott, 2006, Annals of the rheumatic diseases.

Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies.

G A Colditz, G. Colditz, P. Merkel, 2001, The Journal of rheumatology.

Risk factors for serious infections in ANCA-associated vasculitis

P. Merkel, Johannes Leierer, P. Monach, 2023, Annals of the Rheumatic Diseases.

Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis.

P. Merkel, L. Moreland, Marcus Y. Chen, 2019, Rheumatology.

Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3

D. Schroeder, P. Merkel, J. Stone, 2016, Arthritis & rheumatology.

Insulin resistance and hyperinsulinemia precede insulin deficiency in hypertransfused patients with thalassemia major

P. Merkel, 1988 .

Clinical research for rare disease: opportunities, challenges, and solutions.

Peter A Merkel, Jeffrey Krischer, J. Krischer, 2009, Molecular genetics and metabolism.

Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing

P. Merkel, A. Morgan, C. Khor, 2023, Annals of the Rheumatic Diseases.

A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility.

P. Gregersen, C. Wijmenga, J. Barrett, 2015, American journal of human genetics.

MultiPLIER: A Transfer Learning Framework for Transcriptomics Reveals Systemic Features of Rare Disease.

Casey S Greene, Matthias Kretzler, Qiwen Hu, 2019, Cell systems.

Inflammatory and JAK-STAT Pathways as Shared Molecular Targets for ANCA-Associated Vasculitis and Nephrotic Syndrome

Jaclyn N. Taroni, J. Krischer, H. Parikh, 2018, bioRxiv.

Outcome Measures Used in Clinical Trials for Behçet Syndrome: A Systematic Review

P. Merkel, M. Boers, G. Hatemi, 2014, The Journal of Rheumatology.

Urinary Biomarkers in Relapsing Antineutrophil Cytoplasmic Antibody-associated Vasculitis

P. Merkel, K. Maksimowicz-McKinnon, P. Monach, 2013, Journal of Rheumatology.

Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis

J. Krischer, P. Merkel, J. Stone, 2011, Annals of the rheumatic diseases.

Metabolic pathways and immunometabolism in rare kidney diseases

Casey S Greene, Matthias Kretzler, Peter A Merkel, 2018, Annals of the rheumatic diseases.

Readability and Suitability Assessment of Patient Education Materials in Rheumatic Diseases

Peter A Merkel, P. Merkel, H. Schumacher, 2013, Arthritis care & research.

2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

2022 American College of Rheumatology/EULAR Classification Criteria for Takayasu Arteritis

P. Merkel, A. Judge, J. Robson, 2022, Arthritis & rheumatology.

A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.

C. Wijmenga, J. Barrett, B. Lie, 2017, American journal of human genetics.

Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.

P. Merkel, J. Jover, B. Fernández-Gutiérrez, 2007, Arthritis and rheumatism.

Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis

Oliver Distler, Peter A Merkel, M. Mayes, 2017, Journal of scleroderma and related disorders.

Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis

Naoto Hirano, Christopher I. Amos, Xuemei Ji, 2017, Arthritis & rheumatology.

Trends in Long‐Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis With Renal Disease

P. Merkel, R. Falk, S. Hogan, 2016, Arthritis & rheumatology.

Variability of the impact of adverse events on physicians’ decision making

Peter A. Merkel, Liana Fraenkel, Raluca Cozmuta, 2014, BMC Medical Informatics and Decision Making.

Avacopan for the Treatment of ANCA-Associated Vasculitis. Reply.

P. Merkel, P. Bekker, D. Jayne, 2021, The New England journal of medicine.

Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis

P. Merkel, J. Stone, C. Kallenberg, 2020, JCI insight.

Using patient-reported outcomes and PROMIS in research and clinical applications: experiences from the PCORI pilot projects

Emily Moore, Peter A Merkel, Clifton O Bingham, 2016, Quality of Life Research.

Identification of multiple genetic susceptibility loci in Takayasu arteritis.

P. Merkel, J. Guthridge, O. Karadag, 2013, American journal of human genetics.

P. Merkel, J. Stone, C. Kallenberg, 2015, Arthritis & rheumatology.

FRI0331 Apremilast for the treatment of behçet’s syndrome: a phase ii randomized, placebo-controlled, double-blind study

P. Merkel, G. Hatemi, R. Stevens, 2013 .

An international, open label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis (RITAZAREM)

P. Merkel, D. Jayne, R. Smith, 2013 .

Peripheral CD5+ B Cells in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2015, Arthritis & rheumatology.

Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis.

K. Siminovitch, P. Merkel, J. Stone, 2012, Arthritis and rheumatism.

Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis.

P. Merkel, J. Stone, K. Fontaine, 2008, Arthritis and rheumatism.

A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS).

P. Merkel, J. Stone, Y. Min, 2001, Arthritis and rheumatism.

MultiPLIER: a transfer learning framework for transcriptomics reveals systemic features of rare disease

Casey S. Greene, Peter A. Merkel, Qiwen Hu, 2018 .

MultiPLIER: a transfer learning framework reveals systemic features of rare autoimmune disease

Casey S. Greene, Matthias Kretzler, Peter A. Merkel, 2018, bioRxiv.

Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014

P. Merkel, G. Hatemi, G. Mumcu, 2015, The Journal of Rheumatology.

The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis.

P. Merkel, J. Stone, C. Kallenberg, 2018, Clinical journal of the American Society of Nephrology : CJASN.

Developing a Core Set of Outcome Measures for Behçet Disease: Report from OMERACT 2016

P. Merkel, G. Hatemi, P. Cronholm, 2017, The Journal of Rheumatology.

Core Set of Domains for Outcome Measures in Behçet's Syndrome

P. Tugwell, B. Shea, P. Merkel, 2020, Arthritis care & research.

Brief Report: Defining the Nasal Transcriptome in Granulomatosis With Polyangiitis (Wegener's)

Avrum Spira, Yuriy O Alekseyev, Peter A Merkel, 2015, Arthritis & rheumatology.

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials

Ami A. Shah, R. Hubbard, W. Dixon, 2013, Thorax.

Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis.

Stephan Ripke, Delnaz Roshandel, Soumya Raychaudhuri, 2013, Arthritis and rheumatism.

Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis

P. Merkel, K. Maksimowicz-McKinnon, P. Monach, 2012, Annals of the rheumatic diseases.

Development of a provisional core set of response measures for clinical trials of systemic sclerosis

M. Mayes, P. Merkel, J. Varga, 2007, Annals of the rheumatic diseases.

Urine eosinophil‐derived neurotoxin: A potential marker of activity in select eosinophilic disorders

M. Fay, P. Merkel, V. Chinchilli, 2022, Allergy.

Systemic sclerosis - continuing progress in developing clinical measures of response.

P. Merkel, V. Strand, D. Furst, 2007, The Journal of rheumatology.

Clinical Characteristics of an Internet-Based Cohort of Patient-Reported Diagnosis of Granulomatosis With Polyangiitis and Microscopic Polyangiitis: Observational Study

P. Merkel, A. Sreih, J. Springer, 2020, Journal of medical Internet research.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.

P. Merkel, J. Stone, C. Kallenberg, 2015, Journal of the American Society of Nephrology : JASN.

Colchicine myopathy in a patient with familial Mediterranean fever and normal renal function.

J. Corbo, P. Merkel, E. Kissin, 2003, Arthritis & Rheumatism.

Extended Follow-up of Treatment with Rituximab Versus Cyclophosphamide for Remission-Induction of ANCA-Associated Vasculitis : Which Subsets Are At Greatest Risk for Flare?

P. Merkel, J. Stone, C. Kallenberg, 2011 .

Patient-Powered Research Networks of the Autoimmune Research Collaborative: Rationale, Capacity, and Future Directions

P. Merkel, R. McBurney, J. Curtis, 2021, The Patient - Patient-Centered Outcomes Research.

Diagnostic delays in vasculitis and factors associated with time to diagnosis

P. Merkel, Carol A. McAlear, Kalen Young, 2019, Orphanet Journal of Rare Diseases.

Brief Communication: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study.

P. Merkel, J. Stone, John C. Davis, 2005, Annals of internal medicine.

Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy

P. Merkel, Javier Martín, M. González-Gay, 2017, Scientific Reports.

EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis

Shigeto Kobayashi, John McLaren, David Jayne, 2010, Annals of the rheumatic diseases.

Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

B. Rovin, P. Merkel, T. Schall, 2020, ACR open rheumatology.

Comparison of disease activity measures for ANCA-associated vasculitis.

J. Krischer, P. Merkel, J. Stone, 2004 .

Nutrient status of adults with cystic fibrosis.

P. Merkel, C. Gordon, K. Herlyn, 2007, Journal of the American Dietetic Association.

CUTANEOUS MANIFESTATIONS OF ANCA-ASSOCIATED VASCULITIS

P. Merkel, R. Luqmani, R. Watts, 2016 .

Prevalence of antineutrophil cytoplasmic antibodies in patients with various pulmonary diseases or multiorgan dysfunction.

P. Merkel, A. Arroliga, D. Vassilopoulos, 2003, Arthritis and rheumatism.

The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event.

P. Merkel, J. Stone, J. Loscalzo, 2007, The Journal of rheumatology.

Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9

P. Merkel, M. Boers, T. Neogi, 2009, The Journal of Rheumatology.

Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

M. Konig, P. Merkel, J. Stone, 2022, Arthritis & rheumatology.

AB0626 Prevalence of Frailty in an Internet-Based Cohort with a Self-Reported Diagnosis of Vasculitis – The VascStrong Study

P. Merkel, R. Spiera, S. Sattui, 2022, Annals of the Rheumatic Diseases.

Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review of randomized trials.

P. Merkel, R. Christensen, G. Tómasson, 2020, Seminars in arthritis and rheumatism.

Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire

P. Merkel, H. Doll, J. Dawson, 2018, Annals of the rheumatic diseases.

The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.

D. Schroeder, P. Merkel, J. Stone, 2019, Journal of autoimmunity.

Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis

P. Merkel, J. Stone, C. Kallenberg, 2017, American Journal of Nephrology.

Cocaine (Levamisole) Induced Vasculitis

P. Merkel, P. Grayson, 2013 .

Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial.

P. Merkel, P. Bekker, D. Jayne, 2023, The Lancet. Rheumatology.

Patient-Reported Outcomes in Glomerular Disease.

P. Merkel, N. Carlozzi, D. Gipson, 2017, Clinical journal of the American Society of Nephrology : CJASN.

Variability in Experts’ Opinions Regarding Risks and Treatment Choices in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

L. Fraenkel, P. Merkel, R. Cozmuta, 2013, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

Assessment of damage in vasculitis: expert ratings of damage.

P. Merkel, R. Luqmani, D. Jayne, 2009, Rheumatology.

Temporal Trends of Venous Thromboembolism Risk Before and After Diagnosis of Giant Cell Arteritis

P. Merkel, Hyon K. Choi, G. Tómasson, 2017, Arthritis & rheumatology.

Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis.

P. Merkel, J. Stone, John C. Davis, 2008, Arthritis and rheumatism.

Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone

Jeffrey P. Krischer, Peter A. Merkel, Peter C. Grayson, 2020, Trials.

Pulmonary Involvement in Primary Systemic Vasculitides.

P. Merkel, J. Robson, R. Luqmani, 2021, Rheumatology.

Efficacy of leflunomide in the treatment of vasculitis.

P. Merkel, L. Moreland, L. Barra, 2020, Clinical and experimental rheumatology.

FRI0683 DEFINING THE GUT MICROBIOME IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS

P. Merkel, K. Bittinger, J. Lewis, 2019, Epidemiology, risk factors for disease or disease progression.

Medication Interruptions and Subsequent Disease Flares During the COVID‐19 Pandemic: A Longitudinal Online Study of Patients With Rheumatic Disease

P. Merkel, M. Danila, J. Baker, 2021, Arthritis care & research.

The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network

J. Krischer, P. Merkel, H. Jinnah, 2016, Orphanet Journal of Rare Diseases.

Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis.

M. Mayes, P. Merkel, D. Furst, 2015, Rheumatology.

Assessment of health‐related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's)

P. Merkel, J. Stone, M. Boers, 2012, Arthritis care & research.

Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.

M. Mayes, P. Merkel, M. Weisman, 2009, Arthritis and rheumatism.

Diffuse atrophic papules and plaques, intermittent abdominal pain, paresthesias, and cardiac abnormalities in a 55-year-old woman.

P. Merkel, L. Shapiro, E. Cowen, 2016, Journal of the American Academy of Dermatology.

Correlates and Responsiveness to Change of Measures of Skin and Musculoskeletal Disease in Early Diffuse Systemic Sclerosis

M. Mayes, P. Merkel, D. Furst, 2014, Arthritis care & research.

Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.

Richard W. Martin, S. Jimenez, M. Mayes, 1998, Arthritis and rheumatism.

The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis

M. Mayes, P. Merkel, M. Baron, 2016, Arthritis care & research.

Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.

M. Mayes, P. Merkel, C. Denton, 2012, Arthritis and rheumatism.

Comment on: Derivation of an angiographically based classification system in Takayasu's arteritis: reply.

P. Merkel, R. Goel, D. Danda, 2020, Rheumatology.

The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis

P. Merkel, M. Boers, G. Tómasson, 2011, The Journal of Rheumatology.

The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis

M. Mayes, P. Merkel, M. Baron, 2016, Arthritis & rheumatology.

Effect ofMacitentan on the Development of New Ischemic Digital Ulcers in PatientsWith Systemic Sclerosis DUAL-1 and DUAL-2 Randomized Clinical Trials

P. Merkel, D. Furst, C. Denton, 2016 .

POS0070 CONTINUED TREATMENT WITH NINTEDANIB IN PATIENTS WITH LIMITED CUTANEOUS SYSTEMIC SCLEROSIS (lcSSc) AND INTERSTITIAL LUNG DISEASE (ILD)

P. Merkel, M. Aringer, Y. Allanore, 2022, Annals of the Rheumatic Diseases.

Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2017, Arthritis care & research.

Heterotopic ossification in the setting of neuromuscular blockade.

S. Krane, P. Merkel, M. Doyle, 1997, Arthritis and rheumatism.

Use of 18F-fluorodeoxyglucose Positron Emission Tomography to Standardize Clinical Trial Recruitment in Takayasu's Arteritis.

P. Merkel, M. Ahlman, C. Langford, 2022, Rheumatology.

EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update

P. Merkel, A. Vaglio, O. Karadag, 2023, Annals of the Rheumatic Diseases.

Neutrophil extracellular trap formation in anti-neutrophil cytoplasmic antibody-associated and large-vessel vasculitis.

P. Merkel, L. Moreland, P. Monach, 2023, Clinical immunology.

Risk for Cardiovascular Disease Early and Late After a Diagnosis of Giant-Cell Arteritis

P. Merkel, Hyon K. Choi, T. Love, 2014, Annals of Internal Medicine.

Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial.

M. Mayes, P. Merkel, D. Furst, 2008, Arthritis and rheumatism.

Multifocal neutrophilic meningoencephalitis: a novel disorder responsive to anakinra

Z. Mourelatos, P. Merkel, R. Kolster, 2021, Journal of Neurology.

The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica

P. Merkel, R. Black, F. Buttgereit, 2017, The Journal of Rheumatology.

Polymyalgia Rheumatica The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in

P. Merkel, R. Black, C. Hill, 2017 .

Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets

Francis Guillemin, Laure Gossec, Maxime Dougados, 2014, The Journal of Rheumatology.

The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

B. Rovin, P. Merkel, J. Stone, 2016, Arthritis & rheumatology.

Activation of a Latent Epitope Causing Differential Binding of Anti-Neutrophil Cytoplasmic Antibodies to Proteinase 3

P. Merkel, J. Stone, C. Kallenberg, 2022, bioRxiv.

Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis

D. Schroeder, P. Merkel, J. Stone, 2020, Frontiers in Immunology.

Alpha₁-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis.

P. Merkel, J. Stone, J. Edberg, 2010, Arthritis and rheumatism.

Development of Outcome Measures for Large-vessel Vasculitis for Use in Clinical Trials: Opportunities, Challenges, and Research Agenda

P. Merkel, M. Boers, E. Matteson, 2011, Journal of Rheumatology.

Small Vessel Vasculitis

P. Merkel, P. Grayson, 2013 .

P. Merkel, R. Luqmani, D. Jayne, 2011, Arthritis care & research.

Measurement Properties of Outcome Instruments for Large-Vessel Vasculitis: A Systematic Literature Review

P. Merkel, L. Carmona, H. Direskeneli, 2022, The Journal of Rheumatology.

Disease assessment in Takayasu's arteritis.

P. Merkel, H. Direskeneli, S. Aydın, 2013, Rheumatology.

Domain reporting in systemic sclerosis-related Raynaud's phenomenon: An OMERACT scoping review.

P. Merkel, A. Herrick, B. Shea, 2023, Seminars in arthritis and rheumatism.

Severe Small-Vessel Vasculitis Temporally Associated With Administration of Ustekinumab.

P. Merkel, M. Rosenbach, A. V. Van Voorhees, 2016, Journal of drugs in dermatology : JDD.

Ultra-Rare Genetic Variation in Relapsing Polychondritis: A Whole-Exome Sequencing Study

A. Allen, P. Merkel, V. Kraus, 2023, medRxiv.

SAT0012 DETECTION OF CIRCULATING PR3-SPECIFIC B CELLS IN PATIENTS WITH ACTIVE ANCA-ASSOCIATED VASCULITIS

P. Merkel, J. Stone, J. Pers, 2019, SATURDAY, 15 JUNE 2019.

Noninfectious Ascending Aortitis: Staying Ahead of the Curve

P. Merkel, 2009, The Journal of Rheumatology.

Illness Perceptions and Fatigue in Systemic Vasculitis

L. Fraenkel, P. Merkel, R. Richesson, 2013, Arthritis care & research.

OP0021 Draft classification criteria for the anca associated vasculitides

P. Merkel, J. Barrett, A. Judge, 2018, WEDNESDAY, 13 JUNE 2018.

Causal Attributions about Disease Onset and Relapse in Patients with Systemic Vasculitis

L. Fraenkel, P. Merkel, R. Richesson, 2014, The Journal of Rheumatology.

Dynamic Changes in the Nasal Microbiome Associated With Disease Activity in Patients With Granulomatosis With Polyangiitis

Brendan J. Kelly, P. Merkel, K. Bittinger, 2021, Arthritis & rheumatology.

2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis

P. Merkel, A. Judge, J. Robson, 2022, Arthritis & rheumatology.

A small n sequential multiple assignment randomized trial design for use in rare disease research.

Peter A Merkel, Yeh-Fong Chen, Roy N Tamura, 2016, Contemporary clinical trials.

P. Merkel, J. Robson, N. Milman, 2018, Clinical and experimental rheumatology.

Outcome Measures in Large Vessel Vasculitis: Relationship Between Patient‐, Physician‐, Imaging‐, and Laboratory‐Based Assessments

P. Merkel, Casey A. Rimland, M. Ahlman, 2019, Arthritis care & research.

Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes

P. Merkel, J. Dawson, J. Robson, 2019, Patient related outcome measures.

Patient-reported outcomes in Takayasu's arteritis.

P. Merkel, A. Sreih, H. Direskeneli, 2017, Presse medicale.

Assessment of Real-World Patient-Reported Outcomes in Patients Initiating Biologic Agents for the Treatment of Autoimmune Diseases: An Observational Study in Four Patient-Powered Research Networks

P. Merkel, M. Kappelman, D. Cuthbertson, 2023, Patient Related Outcome Measures.

Engaging Multistakeholder Perspectives to Identify Patient‐Centered Research Priorities Regarding Vaccine Uptake Among Adults With Autoimmune Conditions

P. Merkel, R. McBurney, J. Curtis, 2023, ACR Open Rheumatology.

Data linkages between patient-powered research networks and health plans: a foundation for collaborative research

Abiy Agiro, Xiaoxue Chen, Biruk Eshete, 2019, J. Am. Medical Informatics Assoc..

Patient and Physician Global Assessments of Disease Status in Systemic Sclerosis

P. Merkel, M. Baron, D. Khanna, 2022, Arthritis care & research.

Effect ofMacitentan on the Development of New Ischemic Digital Ulcers in PatientsWith Systemic Sclerosis DUAL-1 and DUAL-2 Randomized Clinical Trials

P. Merkel, D. Furst, C. Denton, 2016 .

Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma.

P. Merkel, L. Moreland, P. Nair, 2019, Clinical and experimental rheumatology.

Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2021, JCI insight.

Vitamin D status in ANCA-associated vasculitis

P. Merkel, L. Moreland, P. Monach, 2023, Rheumatology advances in practice.

Domain reporting in Systemic Sclerosis-Related Digital Ulcers: An OMERACT Scoping Review.

P. Merkel, A. Herrick, B. Shea, 2023, Seminars in arthritis and rheumatism.

Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis

P. Merkel, J. Stone, L. Leng, 2018, Arthritis & rheumatology.

J. Krischer, P. Merkel, C. Langford, 2017, Arthritis & rheumatology.

Ocular manifestations of ANCA-associated vasculitis.

P. Merkel, L. Moreland, P. Monach, 2022, Rheumatology.

Brief Report: The Value of a Patient Global Assessment of Disease Activity in Granulomatosis With Polyangiitis (Wegener's)

P. Merkel, J. Stone, John C. Davis, 2014, Arthritis & rheumatology.

Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis

J. Farrar, P. Merkel, L. Moreland, 2019, The Journal of Rheumatology.

083. COMPARISON OF ARTERIAL PATTERNS OF DISEASE IN TAKAYASU’S ARTERITIS AND GIANT CELL ARTERITIS

P. Merkel, L. Moreland, K. Maksimowicz-McKinnon, 2019, Rheumatology.

Corrigendum: Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy

P. Merkel, Javier Martín, M. González-Gay, 2017, Scientific Reports.

SP125THE STEROID TAPERING IN ANCA VASCULITIS EVALUATION STUDY (STAVE) 2: A SYSTEMATIC REVIEW AND META-ANALYSIS

P. Merkel, D. Collister, D. Jayne, 2017 .

P1_185 The Steroid Tapering in ANCA Vasculitis Evaluation Study (STAVE) 2: a Systematic Review and Meta-Analysis

P. Merkel, D. Collister, D. Jayne, 2017 .

EULAR recommendations for the management of primary small and medium vessel vasculitis

H. Raspe, P. Merkel, C. Kallenberg, 2008, Annals of the Rheumatic Diseases.

053. CLINICAL UTILITY OF SERIAL MEASUREMENTS OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES TARGETING PROTEINASE 3 IN ANCA-ASSOCIATED VASCULITIS

D. Schroeder, P. Merkel, J. Stone, 2019, Rheumatology.

LB01THE EFFECT OF PLASMA EXCHANGE ON END STAGE RENAL DISEASE AND DEATH IN PATIENTS WITH SEVERE ANCA ASSOCIATED VASCULITIS

A. Levin, P. Merkel, L. Girard, 2018 .

077. CLASSIFICATION CRITERIA FOR LARGE-VESSEL VASCULITIS

P. Merkel, A. Judge, J. Robson, 2019, Rheumatology.

Bosentan treatment of digital ulcers related to systemic sclerosis : results from the RAPIDS-2 randomised , double-blind , placebo-controlled trial

M. Mayes, P. Merkel, D. Furst, 2010 .

Insulin-resistant syndromes in children.

P. Merkel, W. Tamborlane, S. Caprio, 1993, Hormone research.

Spinal gout presenting as acute low back pain.

P. Merkel, R. Schumacher, Ashwini Komarla, 2013, Arthritis and rheumatism.

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

P. Merkel, J. Stone, D. Scott, 2013, Arthritis and rheumatism.

Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism

P. Merkel, C. Kallenberg, M. Prunotto, 2023, RMD Open.

Direct-to-Consumer Recruitment Methods via Traditional and Social Media to Aid in Research Accrual for Clinical Trials for Rare Diseases: Comparative Analysis Study

J. Krischer, P. Merkel, R. Desnick, 2022, Journal of medical Internet research.

EULAR recommendations for the management of large vessel vasculitis

H. Raspe, P. Merkel, C. Kallenberg, 2008, Annals of the rheumatic diseases.

Comparative Efficacy of Secukinumab Versus Tumor Necrosis Factor Inhibitors for the Treatment of Takayasu Arteritis

P. Merkel, Yangzhong Zhou, Mengtao Li, 2023, Arthritis & rheumatology.

Targeted Program in an Academic Rheumatology Practice to Improve Compliance With Opioid Prescribing Guidelines for the Treatment of Chronic Pain

P. Merkel, M. Ashburn, H. Lacko, 2020, Arthritis care & research.

Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force

H. Raspe, P. Merkel, P. Bacon, 2007, Annals of the rheumatic diseases.

Identification of Susceptibility Loci in IL6, RPS9/LILRB3, and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genome‐Wide Association Study

P. Merkel, J. Wren, T. Vyse, 2015 .

Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss)

P. Merkel, F. Moosig, A. Hot, 2014, Annals of the rheumatic diseases.

The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial.

P. Merkel, D. Murrell, P. Bekker, 2023, The Lancet. Rheumatology.

Development and Validation of a Simulation Model for Treatment to Maintain Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

E. Hyle, P. Merkel, J. Stone, 2023, Arthritis care & research.

361. THE EFFECT OF REDUCED-DOSE ORAL GLUCOCORTICOIDS DURING INDUCTION OF REMISSION INDUCTION IN SEVERE ANCA-ASSOCIATED VASCULITIS

P. Merkel, D. Jayne, M. Walsh, 2019, Rheumatology.

Severe Infection in Antineutrophil Cytoplasmic Antibody-associated Vasculitis

P. Merkel, M. Englund, J. Nilsson, 2017, The Journal of Rheumatology.

Bosentan treatment of digital ulcers related to systemic sclerosis : results from the RAPIDS-2 randomised , double-blind , placebo-controlled trial

M. Mayes, P. Merkel, D. Furst, 2010 .

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials

Ami A. Shah, R. Hubbard, W. Dixon, 2013, Thorax.

Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease

P. Merkel, C. Denton, D. Khanna, 2023, Rheumatology.

Current Status of Outcome Measure Development in Vasculitis

P. Merkel, M. Boers, E. Matteson, 2014, The Journal of Rheumatology.

Identifying Clinical Risk Factors for Opioid Use Disorder using a Distributed Algorithm to Combine Real-World Data from a Large Clinical Data Research Network

R. Duan, J. Tong, Y. Chen, 2020, medRxiv.

Raynaud's Phenomenon

P. Merkel, P. Grayson, 2013 .